# MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/mira-pharmaceuticals-reports-successful-formulation-results-for-skny-1-its-oral-drug/ > **Published:** 2026-07-07T07:28:05-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:49:41-04:00 > **Clinical Summary:** Endocannabinoid obesity treatment shows promising formulation results. Clinical experts explain what this means for patients and the path to human trials. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchDosingSafetyNeurologyMental HealthAnxietyPain Clinical Summary MIRA Pharmaceuticals has achieved promising formulation results for SKNY-1, an oral cannabinoid-based therapeutic candidate designed to modulate the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/). The reported pharmacokinetic findings indicate successful [drug delivery](https://cedclinic.com/cannabinoid-oral-mucosal-delivery-formulation-fabrication/) optimization, which complements previously published preclinical data supporting the compound’s potential efficacy. These formulation advances are significant because they address a key challenge in [cannabinoid therapeutics](https://cedclinic.com/medcan3-trial-cancer-symptoms/): achieving consistent bioavailability and predictable dosing through oral administration, which is the preferred route for most patients. For clinicians considering cannabinoid-based treatments, improved formulation science translates to more reliable therapeutic outcomes and better patient compliance compared to variable cannabis products currently available. The progression from preclinical data to formulation optimization represents movement toward a standardized pharmaceutical product that could eventually provide the safety and efficacy data required for regulatory approval. Clinicians should monitor the continued development of this and similar pharmaceutical-grade cannabinoid candidates, as they may offer a more evidence-based alternative to botanical cannabis for patients who could benefit from [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) modulation. Dr. Caplan’s Take “These formulation results are encouraging from a pharmaceutical development standpoint, but we’re still in preclinical territory, and the jump from bench work to meaningful clinical outcomes in patients is substantial. I’ll be watching closely for human trial data, as that’s when we’ll actually understand whether this approach translates to therapeutic benefit.” Clinical Perspective 💊 While MIRA Pharmaceuticals’ development of SKNY-1 represents a potentially significant advance in targeted [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) modulation through a standardized pharmaceutical formulation, clinicians should recognize that preclinical pharmacokinetic data and successful formulation engineering do not yet establish clinical efficacy or safety in human patients. The transition from bench to bedside for [cannabinoid-based therapeutics](https://cedclinic.com/cannabis-use-disorder-treatment-pipeline-gains-momentum/) remains complex, as the endocannabinoid system’s widespread distribution in the central and peripheral nervous systems creates both therapeutic potential and significant risk for off-target effects, drug-drug interactions, and individual variability in response. Until Phase 1 and 2 [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) are completed and published in peer-reviewed venues, the actual therapeutic profile and tolerability of SKNY-1 in real patients will remain uncertain. In the interim, clinicians should continue to counsel patients seeking cannabis-derived or cannabinoid-based 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20MIRA%20Pharmaceuticals%20Reports%20Successful%20Formulation%20Results%20for%20SKNY-1%2C%20Its%20Oral%20Drug%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68500)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68500)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20MIRA%20Pharmaceuticals%20Reports%20Successful%20Formulation%20Results%20for%20SKNY-1%2C%20Its%20Oral%20Drug%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68500)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [MIRA Pharmaceuticals reports positive preclinical data for Mira-55](https://cedclinic.com/mira-pharmaceuticals-reports-positive-preclinical-data-for-mira-55/) - [In the Mix: 37 More Articles — June 22, 2026](https://cedclinic.com/mixed-cannabis-industry-articles-june-22-2026/) - [Daily Digest: Last 24 Hours: Pain, Policy, and the Psychiatric Tradeoffs of Cannabis — March 01, 2026](https://cedclinic.com/2026-cannabis-psychiatric-tradeoffs-pain-policy/) 📰 Source: [https://www.streetinsider.com/ACCESS+Newswire/MIRA+Pharmaceuticals+Reports+Successful+Formulation+Results+for+SKNY-1%2C+Its+Oral+Drug+Candidate+for+Obesity+and+Addiction/26733375.html](https://www.streetinsider.com/ACCESS+Newswire/MIRA+Pharmaceuticals+Reports+Successful+Formulation+Results+for+SKNY-1%2C+Its+Oral+Drug+Candidate+for+Obesity+and+Addiction/26733375.html) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).